Skip to content
DataLookout
Menu

WaRMINNCT05794399

Anticoagulation in Post MI LV Thrombus Trial in Nepal

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    • Publications: details revised at 14 of 15 entries
  2. Notable Primary completion date: Mar 2025 to Mar 2026
    • Study completion date: Apr 2025 to Apr 2026
    v6
  3. Notable Primary completion date: Mar 2024 to Mar 2025
    • Study completion date: Apr 2024 to Apr 2025
    v5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2023 to Jun 19, 2023
    v4
  5. Notable Start date: Apr 2023 to Jun 2023v3
  6. Minor Study description expanded, about 6 wordsv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

LV thrombus resolution
Timeframe: 3 months

Secondary (2)

Major bleeding events
Embolic events

Arms and interventions

RivaroxabanExperimental

In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with Rivaroxaban 20mg or 15mg as indicated.

WarfarinActive comparator

In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with warfarin with a dose adjusted with the International Normalised ratio range of 2.0 to 3.0.

Drugs: Rivaroxaban, Warfarin

Sites

1 site in 1 country

  • Nepal Health Research CouncilKathmandu, Bagmati, Nepal